Drugs · acquisition-cost intelligence
CILOXAN
ciprofloxacin hydrochloride· ingredient ciprofloxacinAntiinfectives· CIPROFLOXACIN HYDROCHLORIDE 3 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$74.28
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 4 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other ciprofloxacin products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| Cipro | $0.11799 | −$74.16 |
| Ciprofloxacin | $0.11799 | −$74.16 |
| Ciprofloxacin HCl Ophthalmic | $1.62 | −$72.66 |
| Ciprofloxacin Otic | $6.85 | −$67.43 |
| Ciprofloxacin and Dexamethasone | $7.40 | −$66.88 |
| CIPRO HC | $34.87 | −$39.41 |
Medicare Part D coverage · CY2026
On 80 plan formularies · typical tier 3
Prior auth 1% · Step therapy 0% · Quantity limit 9% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.